BioSpace News Archive

New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc (Nasdaq: HZNP), will be presented during an oral plenary presentation at the 89th Annual Meeting of the American Thyroid Association (ATA) in Chicago on Oct. 31.

Kronos Bio, Inc., a developer of first-in-class therapies that modulate historically undruggable targets, announced today that it has expanded its senior management team in newly created positions with the appointments of Christopher Lee, Ph.D. as Vice President, Program Management, and Charles Lin, Ph.D., as Vice President, Biology.

Four oral presentations and eight posters highlight Teva’s commitment to patients with migraine worldwide

Exagen Inc., is pleased to announce clinical study support for Horizon Therapeutics plc to measure methotrexate polyglutamates, the active metabolites of methotrexate in the MIRROR Randomized Controlled Trial Study.

Galen Partners, a healthcare-focused growth equity investment firm, announced today that its portfolio company, SMP Pharmacy Solutions, has completed an acquisition of Northridge Plaza Pharmacy (NPP), a well-known and trusted entity among fertility clinics in California.

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock.

Cesca Therapeutics Inc. announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on Tuesday October 29, at 12:45 pm ET.

Use of oral ibrexafungerp expanded to patients with aspergillosis, coccidioidomycosis, histoplasmosis, blastomycosis and other emerging, difficult-to-treat fungal infections

NanoTouch Materials announced broad support for corporate ESG (environmental, social and governance) initiatives as well as UN SDGs (United Nations sustainable development goals) with their line of self-cleaning surfaces for facilities.

62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence